135 related articles for article (PubMed ID: 1664423)
21. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
Johnson DH; Greco FA; Strupp J; Hande KR; Hainsworth JD
J Clin Oncol; 1990 Oct; 8(10):1613-7. PubMed ID: 2170589
[TBL] [Abstract][Full Text] [Related]
22. Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study.
Niederle N; Ostermann J; Achterrath W; Lenaz L; Schmidt CG
Cancer Chemother Pharmacol; 1991; 28(1):59-62. PubMed ID: 1645622
[TBL] [Abstract][Full Text] [Related]
23. Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.
Johnson DH; DeVore R; Greco FA; Walls J; Thomas M; Hande KR; Hainsworth JD
Semin Oncol; 1992 Feb; 19(1 Suppl 2):50-6. PubMed ID: 1329223
[TBL] [Abstract][Full Text] [Related]
24. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.
Girling DJ
Lancet; 1996 Aug; 348(9027):563-6. PubMed ID: 8774567
[TBL] [Abstract][Full Text] [Related]
25. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
[TBL] [Abstract][Full Text] [Related]
26. [A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
Kado M; Oshima S; Matsui Y; Shimokata K; Hara K; Kanda T; Shima K; Takenaka S
Gan To Kagaku Ryoho; 1986 Jan; 13(1):116-21. PubMed ID: 3002282
[TBL] [Abstract][Full Text] [Related]
27. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
28. The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer.
Clark PI; Cottier B
Semin Oncol; 1992 Dec; 19(6 Suppl 14):36-9. PubMed ID: 1336898
[TBL] [Abstract][Full Text] [Related]
29. Chronic oral etoposide: trials at Indiana University and with the Hoosier Oncology Group.
Loehrer PJ
Semin Oncol; 1992 Dec; 19(6 Suppl 14):48-52. PubMed ID: 1336900
[TBL] [Abstract][Full Text] [Related]
30. Prolonged administration of oral etoposide alone or with intravenous carboplatin in stage IV non-small cell lung cancer: a randomized trial.
Jeremic B; Shibamoto Y; Acimovic L; Milicic B; Milisavljevic S; Nikolic N
Lung Cancer; 1997 Oct; 18(2):179-88. PubMed ID: 9316009
[TBL] [Abstract][Full Text] [Related]
31. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
[TBL] [Abstract][Full Text] [Related]
32. A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: final analysis.
Bardet E; Rivière A; Charloux A; Spaeth D; Ducoloné A; Le Groumellec A; Pellae-Cosset B; Henry-Amar M; Douillard JY
Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):163-8. PubMed ID: 9212019
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
[TBL] [Abstract][Full Text] [Related]
34. Ambulatory combination chemotherapy with oral etoposide and cisplatin for advanced non small cell lung carcinoma patients. A phase II study.
Focan C; Le Hung S; Frere MH; Schallier D
Anticancer Res; 1986; 6(5):977-81. PubMed ID: 3026238
[TBL] [Abstract][Full Text] [Related]
35. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
36. Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer.
Robert F; Wheeler RH; Molthrop D; Bailey A; Chen S
Am J Clin Oncol; 1994 Oct; 17(5):383-6. PubMed ID: 8092106
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
[TBL] [Abstract][Full Text] [Related]
38. Oral etoposide in elderly patients with advanced non small cell lung cancer: a clinical and pharmacological study.
Sorio R; Toffoli G; Crivellari D; Bearz A; Corona G; Colussi AM; Libra M; Talamini R; Veronesi A
J Chemother; 2006 Apr; 18(2):188-91. PubMed ID: 16736888
[TBL] [Abstract][Full Text] [Related]
39. Etoposide and mitomycin in the treatment of non-small-cell lung cancer. A phase I-II evaluation.
Ettinger DS; Bitran JD; Comis RL; Langer CJ; Harwood KV; Harris CL; Keller JH; Losada M
Am J Clin Oncol; 1991 Apr; 14(2):127-32. PubMed ID: 1851388
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of paclitaxel and etoposide for metastatic or recurrent malignancies.
Lilenbaum RC; MacManus D; Engstrom C; Green M
Am J Clin Oncol; 1998 Apr; 21(2):129-34. PubMed ID: 9537196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
